Most people move up to 5 mg and, depending on their progress, might eventually increase to 10 mg or more
While these clinical findings are promising, more research is needed to fully understand the benefits and long-term effects of this peptide combination
Its more likely that the first generic will be available after December 31, 2031
Common side effects may include: nausea diarrhea vomiting constipation decreased appetite abdominal pain fatigue Rare, but serious side effects may include: severe gastrointestinal events leading to dehydration and kidney injury pancreatitis (severe abdominal pain) gallbladder disease severe allergic reactions hypoglycemia when used with insulin or a sulfonylurea diabetic retinopathy complications in those with type 2 diabetes It's easy to get started
In addition, based on clinical research, it is important to identify the syndromes and conditions that can benefit from the KD-based therapies, contraindications for use, KD variants with good effectiveness and tolerability, and factors and biomarkers that can predict KD-related outcomes, which may collectively guide the clinical utilization of the KD in different diseases